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Objective: Controversies regarding the safety, morbidity, and mortality of thoraco-
scopic lobectomy have prevented the widespread acceptance of the procedure. This
series analyzed the safety, pain, analgesic use, and discharge disposition in patients
who underwent thoracoscopic lobectomy and segmentectomy at a single institution.
Methods: We collected data from 153 consecutive patients who underwent thora-
scopic (video-assisted thoracic surgery) lobectomy and assessed the perioperative out-
comes, postoperative pain, and chemotherapy course. A total of 111 of 127 patients
with lung cancer had stage I non–small cell lung cancer. The operative technique
required 2 ports and an access incision (5–8 cm), individual hilar ligation, and lymph
node dissection performed without rib-spreading devices.
Results: There were 9 major complications (6%), including 1 perioperative death
(0.7%). Conversion to thoracotomy occurred in 14 patients (9.2%). Blood transfusion
was required in 11 patients (7%). The median chest tube time was 3 days, and the
length of hospital stay was 4 days; 94.4% of patients went home at the time of dis-
charge, and 5.6% of patients required a rehabilitation facility. At a median postsurgi-
cal follow-up time of 2 weeks, the mean postoperative pain score was 0.6 (0–3), 73%
of patients did not use narcotics for pain control, and 47% of patients did not use any
pain medication. Of patients receiving chemotherapy (N5 26), 73% completed a full
course on schedule and 85% received all intended cycles.
Conclusion: Thoracoscopic (video-assisted thoracic surgery) lobectomy can be per-
formed safely. Discharge independence and low pain estimates in the early postoper-
ative period suggest that this approach may be beneficial. Furthermore, there is a trend
toward improved tolerance of chemotherapy.
T
horacoscopic (video-assisted thoracic surgery [VATS]) lobectomy has been
used in the treatment of lung cancer since the early 1990s and has become
an accepted method of lobectomy.1 Several small VATS series reported that
VATS lobectomy is technically feasible and safe. In our series, the data confirm re-
sults obtained in other retrospective series with regard to low mortality and morbidity.
We provide additional data about postoperative pain control, discharge disposition,
and tolerance of chemotherapy.
Materials and Methods
Patient Selection, Preoperative Studies, Procedure, Perioperative Care
The study population included patients with suspected early-stage (stages IA or IB, clinical
stage I) lung cancer and consisted of 153 patients who underwent an attempted thoracoscopic
lobectomy or segmentectomy in a single tertiary care hospital in New York City between Jan-
uary of 2002 and April of 2006. A total of 127 of these 153 patients had lung cancer. Our lung
cancer cohort during this time period included 199 patients; 37 of these patients were not
eligible for VATS lobectomy because of tumor size or location and underwent lobectomy or
segmentectomy by thoracotomy. Of the 162 remaining patients eligible for VATS, a total of
92 underwent mediastinoscopy. Pathologically positive nodes were found in 35 patients who
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then underwent induction chemotherapy/radiation and were
excluded from the VATS study group. An additional 57 of the
127 VATS lung cancer cohort had negative mediastinoscopies.
Patients were included in the VATS cohort study data if the pre-
operative surgical goal was thoracoscopic lobectomy regardless of
whether the surgery was completed thoracoscopically. However,
if our intention was to perform an exploratory thoracoscopy to
rule out pleural disease, and a subsequent resection by thoracotomy
was performed, the case was excluded from the VATS series.
All patients with stages I and II lung cancer who did not have
contraindications to the procedure were eligible for VATS lobec-
tomy. The VATS study exclusion criteria were the standard absolute
contraindications to VATS lobectomy and included the presence of
T3 or T4 tumors, N3 disease, or inability to achieve single-lung
ventilation. Relative contraindications included central hilar tumors,
tumors that were visible on bronchoscopy or necessitated sleeve
resection, bulky mediastinal or hilar lymphadenopathy, and a history
of neoadjuvant chemotherapy or radiation.
If a conversion was necessary, patients remained in this cohort
on the basis of the principle of ‘‘intention to treat.’’ All cases were
discussed with the operating surgeon. Operative notes were
reviewed, and the goals for the surgical procedures were discussed.
Thus, we were able to distinguish patients who underwent thoraco-
scopy to rule out pleural metastases from those in whom conversions
were performed. The operative goal for all patients with presumed
non–small cell lung cancer (NSCLC) stages I and II was a thoraco-
scopic surgical procedure. The reasons for conversions are listed in
the ‘‘Results’’ section.
Preoperative studies for VATS lobectomy included chest radio-
graph, computed tomography scan, bronchoscopy, pulmonary
function studies, positron emission tomography scan, and other
modalities for metastatic workup when necessary. The type of
surgery performed was individualized to the patient and the tumor.
Most commonly, we performed lobectomies. However, in patients
with poor pulmonary function and smaller tumors, anatomic seg-
mentectomies were performed. A summary of resections performed
by anatomic location is shown in Table 1.
TABLE 1. Resections by anatomic location (n 5 153)
Location Quantity Percent
Right upper lobectomy 56 36.6%
Right middle lobectomy 11 7.2%
Right lower lobectomy 31 20.3%
Left upper lobectomy 26 17.0%
Left lower lobectomy 19 12.4%
Lingulectomy 3 2.0%
Superior segmentectomy left 2 1.3%
Superior segmentectomy right 3 2.0%
Bilobectomy 2 1.3%
Total 153 100.0%The Journal of ThorWe performed bronchoscopy on all patients after intubation
with a double-lumen tube and before repositioning. Mediastino-
scopy was performed on patients with lymph node enlargement
greater than 1 cm or positive lymph-node findings on positron
emission tomography scan. We prefer 3 incisions: an inferior
camera port, a posterior working port, and an anterior access/utility
incision. The avoidance of rib spreading is mandatory or we con-
sider the case a conversion. The first port is the camera port, and it
is usually at the seventh or eighth intercostal space. Ideally, this
port should provide views of the anterior and posterior hila and
should align with the major fissure. We almost exclusively use
a 30-degree thoracoscope. The anterior port is placed directly
over the hilum. It is usually created anterior to the latissimus dorsi
in the fourth intercostal space for upper lobectomies and in the fifth
intercostal space for middle/lower lobectomies. Dissection of both
the hilum and fissure is performed through this port. This initial in-
cision is 1 to 2 cm, and it is extended to 5 to 8 cm in length only if
we proceed with the VATS lobectomy. The third port is usually in
the fifth or sixth intercostal space, either inferior, or posterior, to
the scapular tip. This port usually serves as the lung retraction
port. Individual hilar ligation is performed, and lymph nodes are
dissected.
All patients underwent lymph node dissection. We dissected
lymph nodes 2, 4, and 7 to 12 (or hilar) for right-sided tumors,
lymph node stations 5 to 12 for left-sided tumors, and 4R, 4L,
and 7 for cervical mediastinoscopies. Typically for T1 tumors, we
did not perform routine mediastinoscopy unless the preoperative
computed tomography scan demonstrated lymphadenopathy greater
than 1 cm. We routinely performed mediastinoscopies in patients
with positron emission tomography-positive mediastinal adenop-
athy (standard uptake value . 3) or T2 or greater-sized tumors.
After surgery, all patients recovered in the postoperative anesthesia
care unit and were transferred subsequently to a monitored care
setting.
Chemotherapy
Postoperatively, patients who were eligible received adjuvant che-
motherapy according to the Cancer and Leukemia Group B 9633
North American Intergroup JBR.10 (JBR.10) protocols, namely, 4
cycles of paclitaxel and carboplatin for 12 weeks or 4 cycles of cis-
platin and vinorelbine for 16 weeks, respectively. Most patients
were treated with the Cancer and Leukemia Group B protocol; 1 pa-
tient received the JBR.10 protocol.2,3 The adjuvant chemotherapy
data were collected from patient charts and interviews, and oncolo-
gist interviews. Not all patients received chemotherapy at our insti-
tution, but follow-up was complete and all patients were included.
Postoperative Follow-up Care
Data were obtained and analyzed retrospectively. During postsur-
gical visits, patients were asked by nurse practitioners to grade
their level of pain responses in a questionnaire format. Patients
evaluated their pain levels on a scale of 0 to 3 (0 5 no pain,
1 5 mild pain, 2 5 moderate pain, 3 5 severe pain). In addition,
patients categorized their use of medications for pain relief as
none, nonsteroidal anti-inflammatory agents, opiates, or both.
The postoperative interval of their visit was also recorded. Patients
were contacted with approval of the institutional review board for
chemotherapy, recurrence, and survival data. Individual consent
was waived.acic and Cardiovascular Surgery c Volume 135, Number 3 643
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Major complications were considered mortality, respiratory failure,
empyema, atrial fibrillation requiring cardioversion or anticoagula-
tion, and reoperation. Minor complications were considered pro-
longed air leak, atrial fibrillation not requiring cardioversion and
anticoagulation, pneumonia without respiratory failure, deep vein
thrombosis, urinary tract infection, and cellulitis from intravenous
catheter. These data were collected retrospectively on the basis of
chart review, postoperative follow-up visits, discharge summaries,
and patient interviews.
Statistical Analysis
Medians and ranges are presented for non-normal data. We used the
Kaplan–Meier method to estimate disease-free survivals of patients
with stage I NSCLC who underwent VATS lobectomy. To estimate
disease-free survival, we treated deaths from causes other than lung
cancer as censored observations.
Results
From January of 2002 to April of 2006, 153 patients under-
went thoracoscopic lobectomies at our institution. The series
comprised 67 men and 86 women. The patient characteristics
are shown in Table 2. Of 153 VATS anatomic resections per-
formed, the pathologic diagnosis was NSCLC in 127 patients
(83%) (Table 3). The most common NSCLC was adenocar-
cinoma; other surgical indications included carcinoid tumors,
metastases, and suspicious lesions, usually granuloma or
hamartoma (Table 4). A number of patients with advanced
tumors underwent VATS surgery, which are grouped into
the following categories: oligometastatic disease for which
aggressive treatment is recommended (n 5 2); multiple
nodules but with negative lymph nodes, thereby treating as
synchronous rather than metastatic lesions (n 5 2); false-
negative readings on lymph nodes taken during mediastino-
scopy or an occult metastatic lymph node (n 5 2); and
a significant interval of 11 years between the initial tumor
and the more recent tumor mass (n 5 1).
Hospital Course
The median length of time for chest tube removal was 3
days; the median length of hospital stay was 4 days. Some
52 of 153 patients (34%) were discharged on or before post-
operative day 3; 96 of 144 patients (66.6%) were discharged
TABLE 2. Group characteristics
Characteristic Total/range Median
Age 36–86 67
Male 67
Female 86
FEV1% predicted 29–153 88
ECOG scores 0–2 0
Tumor (cm) 0.6–6.0 2.2
FEV1, Forced expiratory volume in 1 second; ECOG, Eastern Cooperative
Oncology Group.644 The Journal of Thoracic and Cardiovascular Surgery c Mawithout any nursing assistance at home; 40 of 144 patients
(27.8%) were discharged with home assistance; 8 of 144
patients (5.6%) were discharged to a rehabilitation facility.
Of the 40 patients discharged with home assistance, 37
(92.5%) received brief nursing visits (eg, Visiting Nurses
Association of America) and 3 (7.5%) required home assis-
tance for several hours per day.
Mortality and Morbidity
There were no intraoperative deaths. There was 1 postopera-
tive death (0.7%) secondary to respiratory failure from aspi-
ration pneumonia. The most common complications were
atrial fibrillation in 16 of 153 patients (10.5%) and prolonged
air leak more than 7 days in 12 of 153 patients (7.8%). Most
patients with atrial fibrillation had a short course, with a major-
ity requiring chemical cardioversion with amiodarone. Two
patients underwent electrical cardioversion, and 2 patients
were anticoagulated. Some patients experienced more than
1 complication. Other complications are noted in Table 5.
Conversion to Thoracotomy
We considered conversion to include a standard thoracotomy
or a minithoracotomy with any degree of rib spreading. There
were no conversions resulting from the inability to tolerate
single-lung ventilation. In 14 cases (9.2%), the procedure
was converted to either a standard thoracotomy or a minithor-
acotomy for the following reasons: controlled bleeding of
a pulmonary artery branch (n 5 5), cancer involvement of
the hilar structures (n5 6), or other anatomic considerations
TABLE 3. Non–small cell lung cancer stages (n 5 127)
Stage No. Percent
1A 75 59.1%
1B 36 28.3%
2A 5 3.9%
2B 4 3.1%
3A 2 1.6%
3B 2 1.6%
4 3 2.4%
Total 127 100.0%
TABLE 4. Histopathologic diagnosis (n 5 153)
Type No. Percent
Adenocarcinoma 95 62.1%
Squamous cell 21 13.7%
Other NSCLC 11 7.8%
Carcinoid 9 5.9%
Metastases 7 4.6%
Other 9 5.9%
Total 153 100.0%
NSCLC, Non–small cell lung cancer.rch 2008
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control was achieved with a spongestick before conversion
to a standard thoracotomy in 4 patients and minithoracotomy
in 1 patient. Two of 5 patients with pulmonary artery bleed-
ing received a blood transfusion. Overall, blood transfusions
were administered to 11 patients (7.2%), most often second-
ary to significant adhesions or coagulopathy.
Postoperative Pain
At the first postoperative follow-up visit at a median time of 2
weeks (mean 3.1 weeks) postsurgery, patients were asked to
assess their level of pain on a scale of 0 to 3 (05 in no pain;
1 5 in mild pain; 2 5 in moderate pain; 3 5 in severe pain)
The mean pain score based on this scale was 0.6 (median 0;
range 0–3). Patients (N5 145) also reported the medications
they were using for pain relief. At this median follow-up pe-
riod of 2 weeks, 47% of patients were not using any pain
medication, 26% were taking NSAIDs either as needed or
standing order, and 27% reported some narcotic use, with
most, 22%, taking opiates as needed.
Oncologic Results
Of 127 patients with NSCLC who underwent thoracoscopic
lobectomies, 57 (44.9%) had cervical mediastinoscopies,
all of which were negative. Seventy patients did not undergo
mediastinoscopy. The mean number of lymph node stations
sampled from the patients with NSCLC was 4.8 overall
(median, 5.0), including mediastinoscopy and lymph node
dissection. Eleven patients were diagnosed with positive
lymph nodes (11/127; 8.7%) after the thoracoscopic lymph
node dissection; 6 of these patients had negative mediastinos-
copies.
Chemotherapy
Of the 26 patients who received chemotherapy, 19 (73%) re-
ceived their full planned dose on schedule and 3 (12%) were
administered the full course of planned doses of chemother-
apy with a delay in 1 or more cycles. Twenty-two patients
(85%) received all intended cycles with or without delay.
Reasons for dose delay or dose reduction in our series were
neutropenia (n 5 2), gastrointestinal symptoms (n 5 2),
unknown (n 5 3), and a combination of symptoms (n 5 1).
TABLE 5. Complications after surgery (n 5 153)
Complication No. Percent
Atrial fibrillation 16 10.5%
Air leak 12 7.8%
Respiratory failure 3 2.0%
Empyema 2 1.3%
Pneumonia 3 2.0%
Deep vein thrombosis 1 0.7%
Other minor 5 3.3%
Total 42 27.5%The Journal of ThorSurvival
Follow-up was complete for all patients with lung cancer.
The median follow-up time was 14 months (mean: 16
months; range: 1–40 months). Fourteen patients had recur-
rences: 1 of 127 patients (0.8%) had a locoregional recur-
rence at 26 months; 7 of 127 patients (5.5%) had distant
recurrences; and 6 of 127 patients (4.7%) had both locore-
gional and distant recurrences. Our rate of isolated locore-
gional recurrence is low, but because this is a small group
with a short follow-up period, no definite conclusions may
be drawn. Figure 1 summarizes disease-free survival for all
patients with NSCLC (follow-up data are for 124 of 127 pa-
tients; 3 patients had 2 separate lobectomies for metachro-
nous lesions, and survival data are assessed in each case for
only 1 of the 2 surgical procedures). Figure 2 summarizes
all patients with stage I NSCLC.
Discussion
VATS lobectomy should no longer be considered a new tech-
nology; these results and others demonstrate that it has be-
come the preferred approach at many medical centers. Once
the technique is mastered, this surgical procedure can be
performed safely with excellent oncologic and perioperative
outcomes. Discharge independence and low pain estimates in
the early postoperative period suggest this approach may be
beneficial.
One criticism of this surgery is the risk of uncontrolled
bleeding. Although we recognize that this risk exists, it seems
to be minimal and has not been reported in many large series.
Should pulmonary arterial injury occur during a VATS pro-
cedure, control can easily be achieved with a spongestick,
and the surgeon can convert to a thoracotomy. Furthermore,
the safety and efficacy of VATS lobectomy have been dem-
onstrated in several small series, some of these prospective
Figure 1. Disease-free survival in all patients with NSCLC.acic and Cardiovascular Surgery c Volume 135, Number 3 645
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VATS and thoracotomy are similar. Recently, McKenna and
colleagues8 published a large series with excellent perioper-
ative outcomes. Perioperative morbidity and mortality with
VATS lobectomy compare favorably to those of large series
of thoracotomy lobectomies. In the largest series of patients
undergoing lobectomy predominantly by thoracotomy, mor-
bidity ranged from 28% to 38% and mortality ranged from
1.2% to 2.9%.9-11 Other VATS lobectomy series have had
morbidity rates ranging from 9% to 19%, with perioperative
mortality ranging from 0.8% to 1.8%.8,12-15
Oncologic Results
VATS lobectomy is oncologically the same surgical
procedure as a lobectomy through a thoracotomy; both use
anatomic resection, individual hilar ligation, and lymph
node sampling or dissection. Reports indicate that the num-
ber of dissected lymph nodes is similar between VATS lobec-
tomy and thoracotomy.16-18 Uniform lymph node counting
procedures at this institution were established subsequent to
our review so we cannot report the number of lymph nodes
dissected per VATS case here. Five-year survivals are com-
parable and in some cases seemingly better. Walker and
colleagues12 reported a 4-year survival of 78% in 117 pa-
tients with stage I lung cancer, whereas other studies have
reported 5-year survivals as high as 97%.19 This compares
with published 5-year survivals between 61% and 82% for
patients with stage I surgical lung cancer who undergo tho-
racotomy, although admittedly a direct comparison would
be unfair because VATS data are not based on randomized
prospective controlled studies and may be related to patient
selection.20,21
Figure 2. Disease-free survival in patients with stage I NSCLC.646 The Journal of Thoracic and Cardiovascular Surgery c MarPostoperative Pain, Length of Stay, and
Discharge Disposition
The greatest advantage of a VATS lobectomy may be an
improvement in patients’ perioperative quality of life. The
pain associated with this surgery is probably less than that
experienced by patients who undergo thoracotomy and
may in part be explained by decreased inflammation.22
Other series have suggested that this pain is significantly
less in the early postoperative period.4,5,7 In a case-control
study, Demmy and colleagues23 reported similar discharge
data after VATS lobectomies and found that significantly
more patients who underwent thoracotomy required skilled
nursing facilities after surgery. Thus, the data suggest that
these patients have short hospital stays, are discharged with-
out home assistance, and have low opiate requirements.
Chemotherapy
Although we obtained some preliminary data on a small
group of patients who underwent both VATS lobectomy
and adjuvant chemotherapy, we were not able to make any
definitive comparisons with regard to tolerance of chemo-
therapy compared with open lobectomy groups. There are
few data in the literature about how soon after surgery
a patient begins adjuvant chemotherapy, although most trials
seem to start after a postsurgical interval of 6 weeks. Another
recent study reported that patients who underwent VATS had
significantly less dose delay and dose reduction, but the inter-
val to delivery of chemotherapy was not significant.24 In
comparison, the Cancer and Leukemia Group B trial 9633 re-
ported that 55% of patients received full-dose chemotherapy
and the Intergroup JBR.10 trial reported that 45% of patients
had at least 1 dose delay.2,3 Approximately 34% of patients in
the Adjuvant Lung Project Italy series chemotherapy wing
received all scheduled doses without adjustment or delay;
69% completed their treatments with or without adjustments
or delay.25 It is conceivable that patients who undergo VATS
may have a quicker recovery and in general more strength to
tolerate chemotherapy. There are theoretic survival benefits
to starting chemotherapy immediately after surgery because
the body’s tumor burden should be lowest, and tumor growth
fastest, at this time. Thus, chemotherapy administered imme-
diately postsurgery would be most effective, assuming that
wound healing is adequate.
Conclusions
Our data demonstrate that thoracoscopic lobectomy is a safe
procedure with low pain estimates and excellent discharge
independence in the early postoperative period. A multi-
institutional prospective series is warranted to answer the
question of how thoracoscopic lobectomy compares with
open lobectomy in oncologic efficacy, morbidity, and over-
all potential advantages of this approach, including the
timing of postoperative chemotherapy and chemotherapy
tolerance.ch 2008
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